Stoke Therapeutics, Inc.
STOK Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$25.04
KIRA · Stoqly’s AI analyst, in plain words
- Stoke Therapeutics, Inc. had $184M of revenue in fiscal 2025, up 404.5% on the year before.
- Its operating margin was −11.2%, up 266.1 pts: of every 100 in sales, about −11 is left after running the business.
- Stoke Therapeutics, Inc. lost $6.9M in fiscal 2025.
- Free cash flow was $44.9M in fiscal 2025, 24.4% of revenue.
Market cap
$1.7B
P/E
—
Revenue
$184M
Net income
−$6.9M
Free cash flow
$44.9M
Operating margin
−11.2%
Stoke Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+404.5%
Yes. Sales grew 404.5% last year.
Does it make a profit?
−3.7%
No. It lost money last year.
Does profit turn into cash?
24.4%
Yes. 24.4% of sales ends up as free cash.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Stoke Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 16, 2026
- Legal name
- Stoke Therapeutics, Inc.
- CIK
- 0001623526
Stoke Therapeutics, Inc. · STOK
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | $12.4M | $8.8M | $36.6M | $184M |
| Revenue growth | — | — | −29.2% | 316.3% | 404.5% |
| Operating margin | — | −841.2% | −1,307.2% | −277.3% | −11.2% |
| Net income | −$85.8M | −$101M | −$105M | −$89.0M | −$6.9M |
| Net margin | — | −814.7% | −1,192.5% | −243.4% | −3.7% |
| Diluted EPS | −$2.34 | −$2.60 | −$2.38 | −$1.65 | −$0.12 |
| Cash | |||||
| Cash from operations | −$66.9M | −$31.9M | −$81.1M | −$86.9M | $45.6M |
| Capital expenditure | $1.2M | $4.0M | $1.6M | $0.2M | $0.7M |
| Free cash flow | −$68.1M | −$35.8M | −$82.7M | −$87.1M | $44.9M |
| FCF margin | — | −288.8% | −941.7% | −238.1% | 24.4% |
| Share count change | 9.7% | 5.9% | 13.1% | 22.8% | 9.6% |
| Debt and strength | |||||
| Cash and short-term investments | $220M | $230M | $201M | $217M | $285M |
| Shareholders' equity | $218M | $185M | $160M | $229M | $352M |
| Current ratio | 13.4x | 7.8x | 7.0x | 5.8x | 5.3x |
| Interest coverage | — | — | −2,342.3x | −3,898.9x | −2,287.8x |
| Returns and quality | |||||
| Return on equity | −34.1% | −50.2% | −60.8% | −45.8% | −2.4% |
| Return on tangible equity | −39.4% | −54.7% | −65.6% | −38.9% | −2.0% |
| Piotroski F-score | — | — | 1 | 3 | 4 |
| Altman Z'' | 11.6 | 1.7 | −1.4 | 1.9 | 5.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$8.9M
8 insiders
Of sales under plans
83%
$7.4M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Stoke Therapeutics, Inc. · STOK
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $25.04 a share, the company is worth $1.7B.
Source: SEC EDGAR XBRL filings (CIK 0001623526). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.